The Trialbee and Massive Bio’s partnership is set to revolutionise clinical trial recruitment, improving patient access and site efficiency. Credit: Stock-Asso / Shutterstock.

Patient recruitment and enrolment solution Trialbee has entered a collaboration with Massive Bio to leverage its Omnichannel Network to boost access and participant recruitment in clinical trials in the oncology and haematology fields.

This alliance aims to connect cancer patients and their oncologists or haematologists more efficiently to trials.

The companies recognise the low participation rate in cancer clinical research, with only 6.3% of patients involved, as the US Commission on Cancer reported.

Addressing this issue is imperative to increase awareness and access to research opportunities as a viable care option.

Trialbee and Massive Bio are committed to improving patient recruitment for cancer trials, emphasising patient-focused research and complete transparency.

See Also:

This approach ensures clinical sites receive the necessary information to follow up with potential study candidates effectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The partnership will utilise the Trialbee Honey Platform to track and handle interested patients.

This system unifies and standardises recruitment and enrolment information from all sources, offering transparency into the recruitment process and reducing the burden on clinical sites.

In December 2022, Trialbee and Acclinate partnered to increase the equitable participation of patients in trials.

Trialbee CEO Matt Walz said: “We have built our Omnichannel Network to expand the reach of our own data-driving recruitment methods without sacrificing our core principles of being highly targeted in our outreach.

“Massive Bio is a perfect example of a valuable partnership that will open new pathways for patients while still remaining hyper-focused on the ideal participant personae for each clinical trial.

“We are impressed by the team at Massive Bio, and we are proud to collaborate with them to raise awareness of clinical trial opportunities for more, and more diverse, patients and families worldwide.”